← Leaderboards
Georgios Petrides
Mclean Hospital
$10,081,734
Attributed
$14,794,285
Total exposure
7
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2005–23$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$14,794,285 · 7
By mechanism
R01$11,802,716 · 4
U01$1,471,838 · 1
P30$971,907 · 1
R10$547,824 · 1
Top collaborators
- Brent Peter Forester5 shared
Most similar at Mclean Hospital
Same institution · by research overlap
- Dost Ongur$17,996,987
- Brent Peter Forester$10,348,605
- Christian Anthony Webb$7,648,889
- Fei Du$6,859,154
- Zhicheng Carl Lin$5,680,432
Others in their field
Top investigators on “Quality Of Life”
- Gary D Acton · University Of California-Davis$320,373,312
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Gregory H Reaman · National Childhood Cancer Foundation$264,644,476
- David R. Weir · University Of Michigan At Ann Arbor$263,050,576
- Richard K. Wilson · Washington University$198,912,538
Research focus
Quality Of LifePharmaceutical PreparationsAntidepressive AgentsElectroconvulsive TherapyRandomizedCognitionBaseClinical ResearchClinical TrialsSymptomsElderlyMood DisordersPrimary OutcomePublic Health Medicine (Field)ResponsePharmacotherapySecondary OutcomeFunctional DisabilityHuman SubjectPreventSiteResistanceMental DepressionAttention
Grant awards (29)
A Randomized Controlled Trial of Electroconvulsive Therapy plus Usual Care versus Simulated-ECT plus Usual Care for the Acute Management of Severe Agitation in Alzheimer's Dementia (ECT-AD)$1
R01 · FY2023 · AG
A Randomized Controlled Trial of Electroconvulsive Therapy plus Usual Care versus Simulated-ECT plus Usual Care for the Acute Management of Severe Agitation in Alzheimer's Dementia (ECT-AD)$2,324,251
R01 · FY2021 · AG
A Randomized Controlled Trial of Electroconvulsive Therapy plus Usual Care versus Simulated-ECT plus Usual Care for the Acute Management of Severe Agitation in Alzheimer's Dementia (ECT-AD)$2,344,010
R01 · FY2020 · AG
A Randomized Controlled Trial of Electroconvulsive Therapy plus Usual Care versus Simulated-ECT plus Usual Care for the Acute Management of Severe Agitation in Alzheimer's Dementia (ECT-AD)$2,341,700
R01 · FY2019 · AG
A Randomized Controlled Trial of Electroconvulsive Therapy plus Usual Care versus Simulated-ECT plus Usual Care for the Acute Management of Severe Agitation in Alzheimer's Dementia (ECT-AD)$2,415,140
R01 · FY2018 · AG
Trials Operation Unit (OPERATIONS CORE)$200,371
P30 · FY2014 · MH · contact PI
4/8-Prolonging Remission in Depressed Elderly (PRIDE)$262,961
U01 · FY2013 · MH · contact PI
Trials Operation Unit (OPERATIONS CORE)$191,973
P30 · FY2013 · MH · contact PI
4/8-Prolonging Remission in Depressed Elderly (PRIDE)$240,701
U01 · FY2012 · MH · contact PI
4/8-Prolonging Remission in Depressed Elderly (PRIDE)$204,454
U01 · FY2012 · MH · contact PI
Trials Operation Unit (OPERATIONS CORE)$190,791
P30 · FY2012 · MH · contact PI
4/8-Prolonging Remission in Depressed Elderly (PRIDE)$33,054
U01 · FY2012 · MH · contact PI
Trials Operation Unit (OPERATIONS CORE)$18,318
P30 · FY2012 · MH · contact PI
4/8-Prolonging Remission in Depressed Elderly (PRIDE)$240,701
U01 · FY2011 · MH · contact PI
Trials Operation Unit (OPERATIONS CORE)$186,214
P30 · FY2011 · MH · contact PI
4/8-Prolonging Remission in Depressed Elderly (PRIDE)$243,132
U01 · FY2010 · MH · contact PI
Trials Operation Unit (OPERATIONS CORE)$184,240
P30 · FY2010 · MH · contact PI
4/8-Prolonging Remission in Depressed Elderly (PRIDE)$246,835
U01 · FY2009 · MH · contact PI
COMPARING THREE ELECTRODE PLACEMENTS TO OPTIMIZE ECT$163,200
R01 · FY2005 · MH
COMPARING THREE ELECTRODE PLACEMENTS TO OPTIMIZE ECT$163,200
R01 · FY2004 · MH
ECT IN CLOZAPINE REFRACTORY SCHIZOPHRENIA$355,500
R01 · FY2003 · MH
CONTINUATION ECT VS PHARMACOTHERAPY--EFFICACY AND SAFETY$334,136
R01 · FY2003 · MH
COMPARING THREE ELECTRODE PLACEMENTS TO OPTIMIZE ECT$163,200
R01 · FY2003 · MH
ECT IN CLOZAPINE REFRACTORY SCHIZOPHRENIA$355,500
R01 · FY2002 · MH
CONTINUATION ECT VS PHARMACOTHERAPY--EFFICACY AND SAFETY$326,577
R01 · FY2002 · MH
COMPARING THREE ELECTRODE PLACEMENTS TO OPTIMIZE ECT$163,200
R01 · FY2002 · MH
ECT IN CLOZAPINE REFRACTORY SCHIZOPHRENIA$353,101
R01 · FY2001 · MH
CONTINUATION ECT VS PHARMACOTHERAPY--EFFICACY AND SAFETY$277,812
R10 · FY2001 · MH
CONTINUATION ECT VS PHARMACOTHERAPY--EFFICACY AND SAFETY$270,012
R10 · FY2000 · MH